2/25/2014 | CVLM | ViroPharma gets no tenders in offer for 2% convertibles after buyout
|
1/24/2014 | CVLM | ViroPharma tenders for any and all 2% convertibles after acquisition
|
11/14/2013 | CV | ViroPharma's 2% notes convertible in connection with merger agreement
|
11/11/2013 | CV | Market Commentary: Holiday weighs on convertibles liquidity; ViroPharma boosted by Shire acquisition news
|
9/13/2013 | CV | Market Commentary: ViroPharma jumps on takeout chatter; new Protalix moves up outright; GSV Capital gains
|
8/1/2013 | CV | Market Commentary: ViroPharma convertibles add on hedge; Trinity contracts; ArcelorMittal mandatories flat
|
6/17/2013 | CV | Market Commentary: Planned Extra Space reoffered, talk revised; Weyerhaeuser launches deal; Medivation eyed
|
3/20/2013 | BK | ViroPharma lenders agree to waive compliance with financial covenant
|
11/15/2011 | CV | Market Commentary: Goldcorp active; Meritor, ViroPharma shed about a point on swap; Air Lease deal revised
|
9/15/2011 | CVLM | ViroPharma may buy back another $200 million stock or 2% convertibles
|
9/9/2011 | BK | ViroPharma enters $200 million three-year revolver with JPMorgan
|
3/9/2011 | CVLM | ViroPharma may buy back some 2% convertibles via $150 million program
|
1/11/2011 | CV | Market Commentary: Lennar improves on hedge; ViroPharma adds 0.25 point dollar neutral; Sotheby's cheaper
|
10/22/2010 | CV | Market Commentary: SanDisk higher after earnings; ViroPharma up 0.5 point on swap; new Cubist moves above par
|
7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
6/18/2009 | BWCV | ViroPharma says company well positioned for future acquisitions
|
3/24/2009 | CV | ViroPharma buys back $45 million of convertibles due 2017
|
2/9/2009 | CV | Market Commentary: Convertibles little changed ahead of bank plan; Newmont weakens; ViroPharma plunges outright
|
10/22/2008 | SS | Baker Brothers raise stake in ViroPharma
|
10/21/2008 | SS | ViroPharma completes acquisition of Lev Pharmaceuticals
|
9/3/2008 | SS | End of waiting period moves ViroPharma, Lev Pharmaceuticals merger closer to completion
|
7/15/2008 | SS | Market Commentary: Rumors on the telephone; Grey Wolf rejects Basic Energy purchase; ViroPharma snaps up Lev
|
7/15/2008 | SS | ViroPharma to acquire Lev Pharmaceuticals for $442.9 million plus milestone payments for Cinryze
|
8/23/2007 | SP | New Issue: Eksportfinans prices $1.22 million 14.3% reverse convertibles linked to ViroPharma via Natixis
|
3/26/2007 | CV | ViroPharma greenshoe exercised, raising 2% convertibles to $250 million
|
3/21/2007 | CV | Market Commentary: Vornado on tap; Komag jumps in; SL Green, SBA only laggards on new deal train; Freeport up in gray
|
3/21/2007 | CV | New Issue: ViroPharma prices upsized $225 million 10-year senior notes at 2%, up 32.5%
|
3/20/2007 | CV | Market Commentary: Host Hotels up slightly on debut; ViroPharma, Pioneer lead, SBA, ProLogis dull in gray market
|
3/19/2007 | CV | ViroPharma to price $200 million 10-year convertibles Tuesday, talked at 2%-2.5%, up 27.5%-32.5%
|
3/19/2007 | CV | Market Commentary: AtheroGenics falls; Host Hotels, Freeport-McMoran up in gray; ProLogis, ViroPharma, Pioneer plan deals
|
3/19/2007 | CV | ViroPharma files automatic shelf
|
11/10/2006 | BT | ViroPharma dosing patients in phase 2 trial combination of HCV-796, pegylated interferon
|
11/2/2006 | BT | Market Commentary: Exelixis stock off 12% after XL999 trial suspended; ViroPharma reports $23.3 million Q3 net income
|
11/2/2006 | BT | ViroPharma grows cash balance to $224 million during third quarter
|
11/2/2006 | BT | JMP rates ViroPharma at buy
|
10/13/2006 | BT | JMP keeps ViroPharma at market outperform
|
9/29/2006 | BT | JMP keeps ViroPharma at market outperform
|
8/29/2006 | BT | ViroPharma reiterated at market outperform by JMP
|
8/29/2006 | BT | ViroPharma says HCV-796 effective against multiple hepatitis genotypes
|
8/28/2006 | BT | ViroPharma: HCV-796 shows antiviral effects against hepatitis C in phase 1b study
|
8/16/2006 | BT | Market Commentary: CV Therapeutics gains after pricing follow-on; Acadia adds again; Accentia slides
|
8/14/2006 | BT | ViroPharma, Wyeth phase 1b HCV-796 study reaches proof-of-concept milestone, triggers stock purchase
|
8/2/2006 | BT | JMP reiterates ViroPharma at market outperform
|
8/2/2006 | BT | ViroPharma posts $17.2 million second quarter net income, strong Vancocin sales
|
8/1/2006 | BT | Market Commentary: ViroPharma spikes ahead of 2Q; Genomic off on lower outlook; Genitope falls 12% on new data
|
7/13/2006 | BT | ViroPharma says modified bioequivalence standards could have significant health ramifications
|
6/30/2006 | BT | ViroPharma files for stay of action with FDA for Vancocin capsules
|
6/27/2006 | BT | ViroPharma data shows NTCD protects against BI strain of C. difficile in hamster model
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/22/2006 | BT | ViroPharma says HCV-795 shows promising hepatitis C antiviral activity
|
5/5/2006 | BT | JMP reiterates ViroPharma at market outperform
|
5/4/2006 | BT | ViroPharma 1Q net sales of Vancocin up 38.8%, net income falls to $8.2 million
|
5/1/2006 | BT | ViroPharma's HCV-796 phase 1a study supports more trials
|
4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
3/30/2006 | BT | JMP reiterates ViroPharma at market outperform
|
3/29/2006 | BT | ViroPharma phase 2 study shows maribavir has prophylactic properties in cytomegalovirus
|
3/20/2006 | BT | JPM cuts ViroPharma price target
|
3/17/2006 | BT | ViroPharma files petition for stay of action with FDA over generic drug changes
|
2/28/2006 | BT | JMP keeps ViroPharma at market outperform
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/28/2006 | BT | ViroPharma's net income jumps from red to $113.7 million in 2005
|
2/27/2006 | BT | ViroPharma licenses rights to develop C. difficile for treatment of intestinal disease
|
2/7/2006 | BT | FDA grants fast-track status for ViroPharma's maribavir to prevent cytomegalovirus infection
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/26/2006 | CV | Market Commentary: New issues mixed, NRG trades up, UAG flat; Juniper drops; DRS launches $300 million of convertibles
|
1/26/2006 | CV | ViroPharma calls $79 million 6% convertibles due 2007
|
1/19/2006 | BT | Thomas Weisel rates ViroPharma at outperform
|
1/10/2006 | BT | Market Commentary: ViroPharma slips; Panacos zooms; Cephalon soars on short covering; Gilead declines; Celgene retraces
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
12/9/2005 | BT | ViroPharma greenshoe fully exercised, upping stock offer to $173.4 million
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
12/7/2005 | BT | New Issue: ViroPharma sells $150.75 million in upsized follow-on at $16.75, discounted from $17.45 close
|
12/2/2005 | BT | Market Commentary: Inspire sinks; Abgenix off, short interest on the rise; ViroPharma up; Nucryst IPO added to calendar
|
12/1/2005 | BT | OSG Norwich to make Vancocin capsules for ViroPharma under five-year pact
|
11/29/2005 | BT | Market Commentary: InterMune, Valeant slip; Voyager IPO chatted up; Encysive higher; Dendreon, ViroPharma decline
|
11/29/2005 | BT | ViroPharma estimates 2006 Vancocin sales at $160 million to $170 million
|
11/28/2005 | BT | ViroPharma launches follow-on sale of 7 million shares via Goldman Sachs
|
11/28/2005 | BT | ViroPharma completes enrollment for phase 2 maribavir study in bone marrow transplant patients
|
11/10/2005 | BT | ViroPharma phase 1b HCV-796 study shows lower hepatitis C levels in patients
|
11/10/2005 | BT | JMP maintains ViroPharma at outperform
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
11/3/2005 | BT | ViroPharma expands deal to buy $4.5 million more in Vancocin from Eli Lilly
|
10/19/2005 | BT | JMP initiates ViroPharma at market outperform
|
9/15/2005 | BT | Market Commentary: Myogen, Geron follow-ons at bat; ViroPharma up; Advancis almost doubles; GTx launches new deal
|
8/16/2005 | BT | Market Commentary: Kosan retreats further after pulling follow-on; Nektar slips; Acambis off, Electro-Optical IPO seen delayed
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/5/2005 | BTCVPP | ViroPharma to convert 6% convertibles on July 12
|
6/20/2005 | BTCVPP | ViroPharma to automatically convert $18.75 million of 6% convertibles
|
6/16/2005 | BT | Market Commentary: Pfizer purchase spurs speculative buying; Cubist advances; ev3, Micrus, Gentium IPOs discounted
|
6/16/2005 | PP | Market Commentary: Volume bounces back; Gyrus Group leads private placement news with £154 million deal
|
6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
6/9/2005 | CV | Market Commentary: Calpine convertibles mixed after news whammy; market firms on fewer redemptions
|
6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
5/12/2005 | CV | Market Commentary: GM, Ford head renewed move south; Delta convertibles idle after 7.7s swapped for equity
|
5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
5/11/2005 | CV | ViroPharma buys back $29 million 6% convertibles
|
5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
4/6/2005 | PP | New Issue: ViroPharma investors subscribe for $12.5 million in additional notes
|
2/23/2005 | PP | ViroPharma postpones the sale of additional $12.5 million in notes
|
1/19/2005 | PP | Market Commentary: U.S. private placement volume remains weak; Western Canadian plans big deal
|
1/19/2005 | CVPP | New Issue: ViroPharma stockholders approve exchange of notes; company to issue new 2009 notes
|
1/19/2005 | CV | Market Commentary: Alexion goes to 102; Antigenics sweetens terms; Charter exodus continues; auto, airline paper lower
|
10/25/2004 | CV | Market Commentary: Armor overnighter slips in gray market; Isolagen, Option Care deals also emerge
|
10/19/2004 | PP | Buyers for ViroPharma's $62.5 million senior bridge notes identified
|
10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
10/18/2004 | PP | Market Commentary: ViroPharma issues $62.5 million deal; PIPEs volume seen strong
|
10/18/2004 | CVPP | New Issue: ViroPharma sells $62.5 million 10% step-up senior bridge notes
|
8/24/2004 | CV | Market Commentary: Reliant gains on switching out of Calpine; CenterPoint easier; Delta better; ViroPharma gains
|
6/23/2004 | CV | Market Commentary: Calpine powered up by arbs; Matria gains; Nextel Partners soars; two new deals emerge
|
6/23/2004 | CV | ViroPharma pulls exchange
|
6/17/2004 | CV | ViroPharma fixes terms of exchange for convertibles
|
6/15/2004 | CV | ViroPharma extends exchange for convertibles
|
6/9/2004 | CV | ViroPharma fixes terms of exchange for convertibles
|
5/26/2004 | CV | ViroPharma amends exchange for convertibles
|
5/21/2004 | CV | ViroPharma sets pricing in convertibles exchange
|
3/22/2004 | CV | ViroPharma exchange runs through April 26
|
3/19/2004 | CV | ViroPharma plans exchange for 6% convertibles, to sell $25 million new convertibles
|
1/3/2003 | CV | ViroPharma buys back $45.1 million convertibles
|
4/5/2002 | CV | Salomon: Shrinking premiums, rising delta signal times to shift positions
|
3/20/2002 | CV | Market Commentary: Convertibles drop; PDLI joins ViroPharma, other biotechs in freefall
|
3/19/2002 | CV | Market Commentary: Convertibles tread water; Lucent, XM Satellite fall, ViroPharma halted
|